NeuroVive Pharmaceutical AB Ret. on assets
What is the Ret. on assets of NeuroVive Pharmaceutical AB?
The Ret. on assets of NeuroVive Pharmaceutical AB is -36.94%
What is the definition of Ret. on assets?
Return on assets indicates how profitable a company’s assets are in generating revenue. It is computed by dividing net income by average total assets.
ttm (trailing twelve months)
The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.
Ret. on assets of companies in the Miscellaneous sector on LSE compared to NeuroVive Pharmaceutical AB
What does NeuroVive Pharmaceutical AB do?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Companies with ret. on assets similar to NeuroVive Pharmaceutical AB
- Pure Gold Mining has Ret. on assets of -37.06%
- Pure Gold Mining has Ret. on assets of -37.06%
- Chiasma Inc has Ret. on assets of -37.05%
- iSentric has Ret. on assets of -37.04%
- GPS Alliance has Ret. on assets of -37.04%
- Novus Therapeutics Inc has Ret. on assets of -36.97%
- NeuroVive Pharmaceutical AB has Ret. on assets of -36.94%
- Northern Graphite has Ret. on assets of -36.94%
- Imunon Inc has Ret. on assets of -36.94%
- Empire Resources has Ret. on assets of -36.89%
- Colossus Resources Corp has Ret. on assets of -36.88%
- ADTRAN Inc has Ret. on assets of -36.87%
- Fusion Pharmaceuticals has Ret. on assets of -36.87%